RxDoctor Payments Data

Joshua Cohn, MD

Urology · Philadelphia, PANPI 1114156692

Payments from drug & device makers

$4,247in general payments, 2019–2025

Across 106 payments — averaging $40.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Axonics, Inc.$587
  • Coloplast$583
  • Valencia Technologies Corporation$501
  • Dentsply IH AB$314
  • AbbVie$207
  • plus $769 from 15 others

What the payments were for

  • Consulting fees$50112%
  • Speaking & faculty fees$47311%
  • Food & beverage$3,27377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,247 in reported general payments places this provider in the 60th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$257,816
Medicare patients
584
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron231$147,823
MyrbetriqMirabegron167$121,528
Methenamine Hippurate33$4,113
Estradiol51$3,093
RenacidinCitric Ac/Gluconolact/Mag Carb13$2,366
Tamsulosin Hcl121$1,689
Tolterodine Tartrate ErTolterodine Tartrate11$1,683
Lidocaine Hcl14$1,268
Oxybutynin Chloride ErOxybutynin Chloride19$620
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$327
Pentoxifylline12$269
Cephalexin26$126
Levofloxacin15$94
Ciprofloxacin Hcl12$45
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$107$147,823231 claims
Astellas Pharma US IncMyrbetriq$42$121,528167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 596 urology providers in Pennsylvania.

Other urology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →